Sigma Investment Counselors Inc. bought a new position in Amgen, Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 853 shares of the medical research company’s stock, valued at approximately $206,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Balentine LLC increased its position in shares of Amgen by 36.1% during the 3rd quarter. Balentine LLC now owns 181 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 48 shares during the last quarter. Belmont Capital LLC purchased a new stake in Amgen in the fourth quarter worth approximately $36,000. Atwater Malick LLC purchased a new stake in Amgen in the third quarter worth approximately $39,000. Strategic Blueprint LLC bought a new position in Amgen during the third quarter valued at approximately $45,000. Finally, Lenox Wealth Advisors LLC grew its position in Amgen by 53.8% during the third quarter. Lenox Wealth Advisors LLC now owns 246 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 86 shares during the last quarter. Institutional investors and hedge funds own 76.78% of the company’s stock.
In other news, EVP Jonathan P. Graham sold 9,000 shares of Amgen stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $230.54, for a total transaction of $2,074,860.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO David W. Meline sold 8,737 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $234.36, for a total transaction of $2,047,603.32. The disclosure for this sale can be found here. Insiders have sold 18,162 shares of company stock worth $4,214,030 over the last three months. Insiders own 0.25% of the company’s stock.
AMGN has been the subject of a number of recent research reports. BidaskClub lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Tuesday, December 31st. Goldman Sachs Group set a $243.00 target price on shares of Amgen and gave the company a “buy” rating in a report on Monday, September 30th. Mizuho reiterated a “hold” rating and issued a $212.00 target price on shares of Amgen in a research report on Sunday, September 29th. Leerink Swann boosted their price target on shares of Amgen from $189.00 to $205.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Finally, Oppenheimer upped their price target on shares of Amgen from to in a research report on Tuesday. Ten investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Amgen currently has a consensus rating of “Buy” and an average target price of $236.33.
NASDAQ AMGN opened at $237.60 on Wednesday. Amgen, Inc. has a 1 year low of $166.30 and a 1 year high of $244.99. The stock has a market capitalization of $143.49 billion, a PE ratio of 18.23, a PEG ratio of 2.09 and a beta of 1.11. The company has a debt-to-equity ratio of 2.54, a current ratio of 2.89 and a quick ratio of 2.59. The business’s 50-day moving average is $239.07 and its 200 day moving average is $210.46.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 EPS for the quarter, beating analysts’ consensus estimates of $3.53 by $0.13. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.63 billion. During the same quarter in the prior year, the company posted $3.69 EPS. Amgen’s quarterly revenue was down 2.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Amgen, Inc. will post 14.64 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 14th will be given a $1.60 dividend. This is a positive change from Amgen’s previous quarterly dividend of $1.45. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend is Thursday, February 13th. Amgen’s dividend payout ratio (DPR) is currently 40.28%.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: Using other technical indicators with support levels
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.